Health
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies – PRNewswire
/PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the…
NEW BRUNSWICK, N.J., July 30, 2020 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and provi…
-
Business15 hours ago10 ASX shares to buy after the market selloff
-
General18 hours ago‘We are here for you’: PM to bring help to flood zones
-
General17 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
General14 hours agoStephanie Scott’s murder caused a ‘seismic’ shock in Leeton, and the hurt remains